<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Sandesh Parajuli, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel C Brennan, MD, FACP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Christophe Legendre, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John Vella, MD, FACP, FRCP, FASN, FAST
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Albert Q Lam, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 16, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3762625749">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antibody-mediated rejection (ABMR) is the most common cause of immune-mediated allograft failure after kidney transplantation [
         <a href="#rid1">
          1-4
         </a>
         ]. The revised Banff 2017 classification of ABMR defines active (previously called acute) and chronic active ABMR as conditions in which histologic evidence of acute and chronic injury is associated with evidence of current/recent antibody interaction with vascular endothelium and serologic evidence of donor-specific antibodies (DSAs) to human leukocyte antigen (HLA) or non-HLA antigens [
         <a href="#rid5">
          5
         </a>
         ]. These criteria were further refined in the Banff 2019 Kidney Meeting Report [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         The cellular and molecular pathways that regulate ABMR are still under investigation. However, evidence suggests that B cell and plasma cell activation results in the generation of DSAs, which bind to HLA or non-HLA molecules expressed on endothelial cells within the kidney allograft [
         <a href="#rid8">
          8,9
         </a>
         ]. In active ABMR, antibodies bind to graft endothelium and activate complement-dependent and -independent mechanisms that recruit natural killer cells, polymorphonuclear neutrophils, platelets, and macrophages, which contribute to peritubular capillaritis, glomerulitis, cellular necrosis, thrombotic microangiopathy, and a relatively rapid decline in allograft function [
         <a href="#rid8">
          8-10
         </a>
         ].
        </p>
        <p>
         Chronic ABMR, on the other hand, is a pathophysiological process resulting from a repetitive pattern of thrombotic events and inflammatory changes that lead to endothelial cell injury and allograft matrix remodeling [
         <a href="#rid11">
          11,12
         </a>
         ]. It manifests histologically as transplant glomerulopathy and results in a slow and progressive decline in kidney function [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Increasing evidence suggests that the prevention and treatment of antibody-mediated injury requires a combination of strategies to inhibit B cell development, maturation, and activity. Despite a relatively large number of observational studies, it is not clear which combination therapy is the safest and most effective [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The prevention and treatment of active and chronic ABMR of the kidney allograft will be reviewed here. The clinical features and diagnosis of ABMR and the treatment of acute T cell-mediated (cellular) rejection (TCMR) are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">
          "Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7358.html" rel="external">
          "Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1821303944">
         <span class="h1">
          PREDICTORS OF OUTCOME
         </span>
         <span class="headingEndMark">
          —
         </span>
         Active and chronic ABMR are both associated with poor outcomes after kidney transplantation. Patients with active ABMR are at increased risk for subsequent rejection, chronic ABMR, and graft failure [
         <a href="#rid1">
          1,15-18
         </a>
         ]. Similarly, those with chronic ABMR have a higher risk for graft failure and patient death [
         <a href="#rid1">
          1-3,19,20
         </a>
         ]. However, not all patients with ABMR have poor outcomes, and many patients maintain stable allograft function for years after treatment of the initial episode of rejection. Risk factors for graft loss in patients with ABMR are discussed below.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Histologic features
         </strong>
         – Some histopathological features on the kidney biopsy at the time of rejection are associated with worse outcomes. As an example, concurrent, acute T cell-mediated (cellular) rejection (TCMR) is an independent risk factor for graft failure in patients with ABMR [
         <a href="#rid21">
          21
         </a>
         ]. There is also a clear and independent association between microvascular injury and C4d staining (including focal C4d staining in postreperfusion biopsies) with poor outcomes in active or chronic ABMR [
         <a href="#rid22">
          22-25
         </a>
         ]. Similarly, transplant glomerulopathy and the degree of chronic injury (measured semiquantitatively by adding chronic interstitial, tubular, vascular, and glomerular Banff scores) are associated with worse graft survival [
         <a href="#rid19">
          19,26-28
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Donor-specific antibodies
         </strong>
         – Certain characteristics of donor-specific antibodies (DSAs) have been associated with poor outcomes among patients with ABMR. As examples:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DSA strength
         </strong>
         – In a study of 402 consecutive deceased-donor kidney transplant recipients, the risk for both ABMR and graft loss directly correlated with peak preexisting anti-human leukocyte antigen (HLA) DSA strength, as measured by mean fluorescence intensity (MFI) [
         <a href="#rid29">
          29
         </a>
         ]. Patients with a peak anti-HLA DSA MFI of &gt;6000 had a more than 100-fold higher risk for developing ABMR compared with those with an MFI of &lt;465. Graft survival in patients with a peak anti-HLA DSA MFI of &gt;3000 was lower than that of patients with an MFI of ≤3000. However, in the absence of biopsy-proven rejection and acute inflammation, HLA DSA may not be associated with an increased risk of graft failure [
         <a href="#rid30">
          30
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DSA subclass
         </strong>
         – The immunoglobulin subclass of DSA may also predict outcomes although this information may not be provided by all clinical laboratories. In a study of 125 patients with DSAs detected in the first year posttransplant, immunoglobulin G4 (IgG4) immunodominant DSA was associated with later allograft injury, increased allograft glomerulopathy, and interstitial fibrosis/tubular atrophy [
         <a href="#rid31">
          31
         </a>
         ]. By contrast, IgG3 immunodominant DSA was associated with a shorter time to rejection, increased microvascular injury, C4d capillary deposition, and graft failure. These findings suggest that IgG immunodominant DSA subclasses may identify distinct phenotypes of kidney allograft antibody-mediated injury.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Complement-binding capacity
         </strong>
         – The ability of anti-HLA DSAs to bind complement, as determined by the C1q assay, may identify patients at high risk for kidney allograft loss [
         <a href="#rid32">
          32
         </a>
         ]. However, one study showed that the C1q-binding activity of DSAs largely reflects differences in antibody strength, questioning the biologic significance of the C1q assay [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DSA type
         </strong>
         – The type of DSA (preexisting or de novo) may also be a predictor of worse outcomes in patients with ABMR. ABMR in patients with a de novo DSA, which is thought to be mostly related to medication nonadherence or inadequate immunosuppression, has been associated with poorer outcomes compared with ABMR in patients with preexisting DSA (ie, presensitized patients) [
         <a href="#rid1">
          1,28,34-36
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          DSA response to treatment
         </strong>
         – There is accumulating evidence indicating that a decline in DSA strength after treatment is associated with better graft survival [
         <a href="#rid28">
          28,37,38
         </a>
         ]. However, there is limited information on the definition of a validated positive DSA response.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Graft function
         </strong>
         – The degree of kidney allograft dysfunction at the time of kidney biopsy appears to be directly associated with poor outcomes in patients with ABMR [
         <a href="#rid19">
          19,25,34,39
         </a>
         ]. As an example, in a retrospective analysis of 205 patients with biopsy-proven ABMR, an estimated glomerular filtration rate (eGFR) of &lt;30 mL/min per 1.73 m
         <sup>
          2
         </sup>
         at diagnosis and a urine protein-to-creatinine ratio of ≥0.30 g/g at the time of biopsy were identified as independent determinants of allograft loss (hazard ratio [HR] 3.27 and 2.44, respectively) [
         <a href="#rid34">
          34
         </a>
         ]. In another study of 123 patients with chronic ABMR, a serum creatinine of &gt;3 mg/dL and urine protein-to-creatinine ratio of &gt;1 g/g at the time of diagnosis were independently associated with graft loss [
         <a href="#rid19">
          19
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One study of 91 patients with active ABMR found that changes in eGFR following the diagnosis of ABMR could predict the risk of subsequent death-censored graft failure using a joint modeling framework [
         <a href="#rid40">
          40
         </a>
         ]. An extrapolated 30 percent improvement in the slope of eGFR in the first 12 months was associated with a 10 percent reduction in death-censored graft failure at five years [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Molecular markers
         </strong>
         – Several invasive and noninvasive molecular markers are being explored as both diagnostic and prognostic tools in patients with ABMR. The expression of endothelial cell-associated transcripts and DSA-selective transcripts has been shown to be biomarkers of active antibody-mediated injury and may predict worse graft outcomes [
         <a href="#rid26">
          26,41
         </a>
         ]. These molecular assays, which are not yet in mainstream clinical practice, reflect changes in microcirculatory endothelium not normally detected by routine histopathology and DSA testing and may improve risk stratification and prognostication in patients with ABMR. A multiorgan transplant gene panel, called the Banff Human Organ Transplant panel, is being considered by the Banff committee [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Donor-derived cell-free DNA (dd-cfDNA) represents nonencapsulated, fragmented DNA that is continuously shed into the bloodstream from the allograft undergoing injury, with a half-life of approximately 30 minutes. Several assays for measuring dd-cfDNA are available and have been approved by Medicare for use in transplant recipients [
         <a href="#rid42">
          42
         </a>
         ]. In a study of 1092 kidney transplant recipients whose dd-cfDNA levels were monitored over three years, dd-cfDNA levels of ≥0.5 percent were associated with a nearly threefold increased risk of developing a de novo DSA [
         <a href="#rid43">
          43
         </a>
         ]. Persistently elevated dd-cfDNA levels were associated with &gt;25 percent decline in the eGFR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While the growing number of molecular and multimodality tests offers the advantage of prospective noninvasive monitoring and personalized medicine, further studies are needed to consider the cost and long-term utility of these assays.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prediction models
         </strong>
         – Novel models are being developed to predict long-term kidney allograft failure, including after the treatment of rejection [
         <a href="#rid44">
          44
         </a>
         ]. Using an international cohort study including 7557 kidney transplant recipients from 10 academic medical centers from Europe and the United States, 32 candidate prognostic factors for kidney allograft survival were assessed. Of these, eight functional, histologic, and immunological prognostic factors were independently associated with allograft failure and were then combined into a risk prediction score (iBox). This score showed accurate calibration and discrimination (C-index 0.81, 95% CI 0.79-0.83). The iBox system showed accuracy when assessed at different times of evaluation posttransplant and was validated in different clinical scenarios including response to rejection therapy, suggesting that the iBox risk prediction score may help to guide monitoring of patients and further improve the design and development of a valid and early surrogate endpoint for clinical trials [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3027658955">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to the prevention of ABMR depends upon the detection of donor-specific antibody (DSA) prior to (preexisting DSA) or after (de novo DSA) transplant.
        </p>
        <p class="headingAnchor" id="H64238091">
         <span class="h2">
          Patients with preexisting DSA before transplant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with a preexisting donor-specific antibody (DSA) prior to transplant have a greater risk for ABMR and graft failure compared with nonsensitized patients [
         <a href="#rid45">
          45-47
         </a>
         ]. This risk is proportional to the strength of DSA as patients with a positive complement-dependent cytotoxicity (CDC) crossmatch have a higher risk of ABMR and graft loss than those with a positive flow crossmatch, who in turn have a higher risk than patients with a positive virtual crossmatch (antibodies detected by single antigen bead technology) [
         <a href="#rid45">
          45,46,48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/116878.html" rel="external">
          "Kidney transplantation in adults: Overview of HLA sensitization and crossmatch testing", section on 'Assays for crossmatch testing'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to prevention
         </strong>
         – Although a common approach to prevent ABMR has been to avoid transplanting highly sensitized patients, this option renders chronic dialysis the only therapeutic option, with significant implications for patient health, quality of life, and health care costs. Long-term survival in kidney transplant recipients has improved considerably with desensitization [
         <a href="#rid49">
          49,50
         </a>
         ], which can be used to reduce the level of DSAs pretransplant. In addition, the enrollment of patients in special programs to optimize matching can lead to timely transplants with better outcomes. (See
         <a class="medical medical_review" href="/z/d/html/7351.html" rel="external">
          "Kidney transplantation in adults: HLA-incompatible transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7311.html" rel="external">
          "Kidney transplantation in adults: Living unrelated donors", section on 'Kidney paired donation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Our general approach to the prevention of ABMR in patients with a preexisting DSA prior to transplant is as follows:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients
         <strong>
          with
         </strong>
         a potential living donor, the approach depends upon the results of the most recent crossmatch:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In patients with a positive CDC crossmatch
         <strong>
          or
         </strong>
         a strongly positive flow crossmatch, we, and many other transplant centers, prefer to use kidney paired donation (KPD) programs, rather than desensitization, given the high risk of ABMR and graft loss in such patients [
         <a href="#rid51">
          51-53
         </a>
         ]. Such KPD programs (including the National Kidney Registry, the Alliance for Paired Donation, and single-center programs) enable sensitized patients with immunologically incompatible living donors to be transplanted from other living donors in similar situations who are willing to exchange organs. Although cost has been a concern for kidney exchange registries in the United States, KPD could help participating centers to avoid complex desensitization protocols while improving long-term outcomes. Mathematical modeling has predicted that an optimized matching algorithm and a national KPD program would improve graft outcomes and reduce health care costs for highly sensitized patients [
         <a href="#rid54">
          54
         </a>
         ]. Some transplant centers combine desensitization and KPD.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In patients with a positive virtual crossmatch (antibodies detected by single antigen bead technology) or a mild to moderate flow crossmatch (ie, median channel shift of &lt;200), we employ human leukocyte antigen (HLA) desensitization strategies, which include treatment with plasmapheresis,
         <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">
          rabbit antithymocyte globulin
         </a>
         (rATG)-Thymoglobulin, and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid23">
          23,48
         </a>
         ]. This is discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7351.html" rel="external">
          "Kidney transplantation in adults: HLA-incompatible transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In patients
         <strong>
          without
         </strong>
         a potential living donor, we employ HLA desensitization strategies. (See
         <a class="medical medical_review" href="/z/d/html/7351.html" rel="external">
          "Kidney transplantation in adults: HLA-incompatible transplantation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         In
         <strong>
          all
         </strong>
         patients with a preexisting DSA before transplant who undergo kidney transplantation, we use induction and maintenance immunosuppression therapies that are appropriate for patients at
         <strong>
          high risk
         </strong>
         for the development of acute rejection [
         <a href="#rid55">
          55
         </a>
         ]. The selection of induction and maintenance immunosuppression in high-risk kidney transplant recipients is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7353.html" rel="external">
          "Kidney transplantation in adults: Induction immunosuppressive therapy", section on 'Patients at high risk of rejection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">
          "Kidney transplantation in adults: Maintenance immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring after transplant
         </strong>
         – The monitoring of kidney allograft function in patients with a preexisting DSA before transplant is similar to that performed in nonsensitized patients (see
         <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">
          "Overview of care of the adult kidney transplant recipient", section on 'Monitoring kidney allograft function'
         </a>
         ). In addition, we routinely monitor DSA levels at months 1, 3, 6, and 12 posttransplant and then annually [
         <a href="#rid56">
          56
         </a>
         ]. In patients with a significant rise in DSA or who develop a de novo DSA within the first three months, we perform a kidney allograft biopsy. This practice is largely consistent with the recommendations of the Consensus Guidelines on the Testing and Clinical Management Issues Associated with HLA and Non-HLA Antibodies in Transplantation [
         <a href="#rid56">
          56
         </a>
         ]. Patients with a pretransplant DSA undergo protocol kidney biopsies at months 3 and 12 posttransplant.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some UpToDate contributors to this topic perform a postreperfusion kidney allograft biopsy at the time of transplantation to identify patients at risk for ABMR [
         <a href="#rid23">
          23
         </a>
         ]. In patients who are found to have evidence of positive C4d staining, plasmapheresis (two to three sessions), intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), and a single dose of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         375 mg/m
         <sup>
          2
         </sup>
         (administered after the last session of plasmapheresis) would be added to the induction immunosuppression regimen [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1190802991">
         <span class="h2">
          Patients with de novo DSA after transplant
         </span>
         <span class="headingEndMark">
          —
         </span>
         Kidney transplant recipients who develop a de novo donor-specific antibody (DSA) after transplantation can present with late-onset ABMR. As mentioned above, ABMR in patients with a de novo DSA has been associated with poorer outcomes compared with ABMR in patients with preexisting DSA (see
         <a class="local">
          'Predictors of outcome'
         </a>
         above). The two most common causes of ABMR due to a de novo DSA are medication nonadherence and inadequate immunosuppression, the latter of which is frequently attributed to the use of minimization strategies. In addition, acute T cell-mediated (cellular) rejection (TCMR), malignancy, and opportunistic infections (such as BK polyomavirus and cytomegalovirus [CMV] infection) that require a reduction in immunosuppression may also influence the development of late-onset ABMR [
         <a href="#rid1">
          1,2,57,58
         </a>
         ].
        </p>
        <p>
         Prevention of ABMR should focus on addressing nonadherence and under-immunosuppression while balancing the safety and efficacy of long-term immunosuppression. We maintain the majority of our patients on a triple therapy immunosuppression regimen (
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         , and
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         ) and monitor whole blood tacrolimus levels monthly in the first three years posttransplant and every three months thereafter. In patients who do not tolerate tacrolimus, we switch to
         <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">
          belatacept
         </a>
         rather than
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         or
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         . We monitor DSA annually and perform kidney allograft biopsies in all patients who develop a de novo DSA. (See
         <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">
          "Kidney transplantation in adults: Maintenance immunosuppressive therapy"
         </a>
         .)
        </p>
        <p>
         An analysis of two randomized trials showed that the conversion of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         to
         <a class="drug drug_general" data-topicid="9078" href="/z/d/drug information/9078.html" rel="external">
          everolimus
         </a>
         at 3 to 4.5 months after transplant was associated with significantly higher rates of de novo DSA (11 versus 23 percent) and ABMR (3 versus 13 percent) [
         <a href="#rid59">
          59
         </a>
         ]. By contrast, treatment with
         <a class="drug drug_general" data-topicid="16790" href="/z/d/drug information/16790.html" rel="external">
          belatacept
         </a>
         , a selective costimulation blocker that targets the CD80/CD86-CD28 interaction to prevent T cell activation, was associated with a low rate of de novo DSA over seven years of treatment in phase III trials, although this was not an initial endpoint of those studies [
         <a href="#rid60">
          60
         </a>
         ]. Although there has been no head-to-head comparison between
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         and belatacept, these data suggest that costimulation blockade may be safe and effective in preventing de novo DSA and late ABMR. Similarly, glucocorticoid withdrawal or avoidance may not increase the risk of de novo DSA if adequate immunosuppression is otherwise maintained, although this is difficult to standardize. In a five-year, longitudinal study, 37 kidney transplant recipients were randomly assigned to chronic glucocorticoid therapy or early glucocorticoid withdrawal at day 7 posttransplant; all patients received rATG-Thymoglobulin for induction and tacrolimus and
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         as maintenance immunosuppression [
         <a href="#rid61">
          61
         </a>
         ]. Only one patient in the chronic glucocorticoid treatment arm and none in the glucocorticoid withdrawal arm developed a de novo DSA.
        </p>
        <p class="headingAnchor" id="H3858593764">
         <span class="h1">
          TREATMENT OF ACTIVE ANTIBODY-MEDIATED REJECTION
         </span>
        </p>
        <p class="headingAnchor" id="H117657109">
         <span class="h2">
          Goals of therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary goal of treating ABMR is to reduce the titer of existing pathogenic donor-specific antibodies (DSAs), to eradicate the clonal population of B cells or plasma cells that is responsible for their production, to prevent complement activation and reduce endothelial injury, and to preserve graft function [
         <a href="#rid14">
          14
         </a>
         ]. For most patients, this involves treatment with the combination of glucocorticoids and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG), with the addition of plasmapheresis and/or
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         in selected patients. However, complete elimination of DSA commonly does not occur, and to attempt it may lead to dangerous over-immunosuppression. In general, we treat
         <strong>
          all
         </strong>
         patients who have evidence of active ABMR on biopsy. Although we do not routinely perform surveillance or protocol allograft biopsies at our institution, we would treat patients who are discovered to have subclinical ABMR by surveillance biopsy. In addition, we treat patients with C4d-negative ABMR with the same approach that we use in patients with C4d-positive ABMR. (See
         <a class="local">
          'Patients with subclinical rejection'
         </a>
         below and
         <a class="local">
          'Patients with C4d-negative ABMR'
         </a>
         below.)
        </p>
        <p>
         The optimal treatment of active ABMR is unclear, and there have been no large randomized, controlled trials comparing the safety and efficacy of different therapeutic strategies [
         <a href="#rid62">
          62
         </a>
         ]. Our recommendations for the treatment of ABMR are primarily based upon available, low-quality evidence and are largely consistent with the 2009 Kidney Disease: Improving Global Outcomes clinical practice guidelines and the 2019 Transplantation Society Working Group Expert Consensus [
         <a href="#rid14">
          14,63
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H420157826">
         <span class="h2">
          Approach to initial therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although patients could be treated on an outpatient basis, we advocate inpatient admission for patients with comorbidities such as diabetes because of the complexity of the treatment regimen. Our approach to the initial treatment of active ABMR depends upon the timing of the diagnosis of ABMR (
         <a class="graphic graphic_algorithm graphicRef116370" href="/z/d/graphic/116370.html" rel="external">
          algorithm 1
         </a>
         ). At our centers, we consider ABMR that presents within the first posttransplant year to be early-onset ABMR and ABMR that presents after the first posttransplant year to be late-onset ABMR. However, there is no uniform consensus as to what time threshold determines early versus late ABMR, and other centers may use different thresholds.
        </p>
        <p class="headingAnchor" id="H3910021621">
         <span class="h3">
          Patients who are ≤1 year posttransplant
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients who are diagnosed with active ABMR within the first year posttransplant (early onset), we suggest initial therapy with the combination of glucocorticoids, plasmapheresis, and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         rather than other therapies. In addition, some experts administer
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         if the patient is younger (eg, age &lt;70 years), has better allograft function (eg, estimated glomerular filtration rate [eGFR] ≥20 mL/min/1.73 m
         <sup>
          2
         </sup>
         and lower chronicity scores on biopsy [ie, interstitial fibrosis + tubular atrophy + fibrous intimal thickening + allograft glomerulopathy &lt;8]), and has evidence of severe disease (eg, higher DSA, diffuse C4d staining, or more extensive microvascular inflammation [ie, glomerulitis score + peritubular capillary score ≥4] on biopsy) [
         <a href="#rid64">
          64
         </a>
         ]. For all patients, we augment other components of maintenance immunosuppression as needed, as discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">
          "Kidney transplantation in adults: Maintenance immunosuppressive therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing of glucocorticoids
         </strong>
         – We give intravenous (IV)
         <a class="drug drug_general" data-topicid="9639" href="/z/d/drug information/9639.html" rel="external">
          methylprednisolone
         </a>
         at a dose of 300 to 500 mg daily for three to five days, followed by a rapid oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         taper to the patient's previous maintenance dose of prednisone. If there are no concerns for nonadherence, we augment the maintenance prednisone dose. As an example, if the rejection occurred while the patient was taking 5 mg/day, we would increase the maintenance prednisone to 7.5 to 10 mg/day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Plasmapheresis regimen
         </strong>
         – Plasmapheresis is performed daily or every other day for a maximum of six sessions [
         <a href="#rid65">
          65
         </a>
         ] or until the serum creatinine is within 20 to 30 percent of the baseline. The initial treatment is typically a one-and-one-half-volume exchange with albumin, and subsequent treatments are a one-volume exchange with albumin. We prefer an every-other-day plasmapheresis schedule as albumin alone can often be administered for replacement with interval recovery of the prothrombin time, partial thromboplastin time, and fibrinogen to acceptable levels without the need to administer fresh frozen plasma. This avoids the risk of antigen sensitization; however, one to two units of fresh frozen plasma may be used for replacement at the end of a plasmapheresis treatment to reduce bleeding risk in the appropriate clinical setting, such as a same-day kidney allograft biopsy. (See
         <a class="medical medical_review" href="/z/d/html/7941.html" rel="external">
          "Therapeutic apheresis (plasma exchange or cytapheresis): Indications and technology"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing of
         </strong>
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         <strong>
         </strong>
         – We administer IVIG at a dose of 100 mg/kg after each session of plasmapheresis. We typically give 500 mg/kg per day for one to two days after the final session of plasmapheresis, with a total cumulative target dose of at least 1000 mg/kg of IVIG. In patients with obesity, some centers determine the IVIG dose based upon the patient's ideal body weight (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ). Sucrose-free IVIG solutions that are no more than 5 percent concentrated are preferred, to decrease the risk of acute kidney injury. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects", section on 'Acute kidney injury'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing of
         </strong>
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         <strong>
         </strong>
         – If rituximab is given, we administer a single dose of either 200 mg or 375 mg/m
         <sup>
          2
         </sup>
         after completion of plasmapheresis and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         We do
         <strong>
          not
         </strong>
         routinely use immunoadsorption, proteasome inhibitors, interleukin (IL)-6 blockade, complement inhibitors, or splenectomy in the initial treatment of patients with ABMR. However, some these therapies can be considered in patients who do not respond to initial treatment. (See
         <a class="local">
          'Second-line therapies for refractory ABMR'
         </a>
         below and
         <a class="local">
          'Less frequently used therapies'
         </a>
         below.)
        </p>
        <p>
         There is no high-quality evidence to guide the optimal therapy of patients with active ABMR. The best data come from the following studies, which included patients with ABMR diagnosed within or after the first year posttransplant:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 systematic review that included 10 randomized and 11 nonrandomized, controlled trials evaluated the effects of different treatments on graft survival among kidney transplant recipients with active ABMR [
         <a href="#rid66">
          66
         </a>
         ]. All of the randomized trials were small, and the criteria used for the diagnosis of ABMR varied among studies. Five randomized trials assessed the benefit of antibody removal by plasmapheresis (four trials) or immunoadsorption (one trial) on graft survival. The estimated pooled effect did not suggest improved graft survival with antibody removal (hazard ratio [HR] 0.76, 95% CI 0.35-1.63). However, the control group was different for each trial, and among the trials evaluating plasmapheresis, the plasmapheresis regimen differed in dose, frequency, and treatment interval. A sensitivity analysis of the three trials with longer follow-up (two to five years) suggested a benefit with antibody removal (HR 0.46, 95% CI 0.26-0.82).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two retrospective studies evaluated the effects of plasmapheresis and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         on long-term graft survival among patients with acute ABMR, chronic ABMR, or features of both. In one study of 35 patients with ABMR (diagnosed at a mean of 59 months after transplant), treatment with plasmapheresis and IVIG was associated with better 10-year graft survival compared with treatment without plasmapheresis and IVIG (74 versus 35 percent) [
         <a href="#rid67">
          67
         </a>
         ]. A second study detected no difference in graft failure between patients treated with plasmapheresis and IVIG with or without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         and those receiving no specific treatment [
         <a href="#rid68">
          68
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The benefit of a combination therapy including plasmapheresis,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was suggested by an observational study from France that compared the efficacy of plasmapheresis/IVIG/rituximab versus high-dose IVIG alone in the treatment of ABMR; all patients received pulse glucocorticoids [
         <a href="#rid69">
          69
         </a>
         ]. The median onset of ABMR in both treatment groups was 15 days after transplantation. Graft survival at 36 months was 92 percent among patients treated with plasmapheresis/IVIG/rituximab versus 50 percent of those treated with IVIG alone. At three months posttreatment, DSAs were significantly lower in the plasmapheresis/IVIG/rituximab group. Another study confirmed that patients with active clinical or subclinical ABMR in the first year posttransplant have better outcomes if treated with a combination strategy including plasmapheresis [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase III, multicenter, randomized, placebo-controlled trial examined the effect of
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         among 38 kidney transplant recipients with biopsy-proven, active ABMR [
         <a href="#rid71">
          71
         </a>
         ]. Patients were randomly assigned to rituximab (375 mg/m
         <sup>
          2
         </sup>
         ) or placebo at day 5 of treatment; all patients were treated with plasmapheresis,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and glucocorticoids. ABMR occurred within the first three months of transplant in 58 and 53 percent of patients in the rituximab and placebo groups, respectively. There was no difference between the two groups in the frequency of the primary endpoint, defined as a composite measure of graft loss or absence of improvement in kidney function at day 12 (53 and 58 percent of patients in the rituximab and placebo groups, respectively). Long-term follow-up of the patients found no difference in death-censored graft survival or kidney function at seven years [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an observational study of 78 patients with ABMR diagnosed &gt;3 months after transplant (mean of 7.3 years, range 3 months to 27 years) who were treated with glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , there was no significant difference in kidney function at 6 and 12 months after ABMR between patients receiving and those not receiving rituximab treatment [
         <a href="#rid64">
          64
         </a>
         ]. However, beyond 12 months of follow-up, treatment with rituximab was associated with improved graft survival (85 versus 68 percent, respectively), suggesting a delayed benefit with rituximab.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1124581968">
         <span class="h3">
          Patients who are &gt;1 year posttransplant
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients who are diagnosed with active ABMR after the first year posttransplant (late onset), we suggest initial therapy with glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         rather than glucocorticoids, IVIG, and plasmapheresis. We do not perform plasmapheresis in such patients because of the lack of evidence supporting the safety and efficacy of plasmapheresis in later-onset ABMR. However, some transplant centers continue to administer plasmapheresis for ABMR diagnosed after one year posttransplant. In addition, some experts administer
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         if the patient is younger (eg, age &lt;70 years), has better allograft function (eg, eGFR ≥20 mL/min/1.73 m
         <sup>
          2
         </sup>
         and lower chronicity scores on biopsy [ie, interstitial fibrosis + tubular atrophy + fibrous intimal thickening + allograft glomerulopathy &lt;8]), and has evidence of severe disease (eg, higher DSA, diffuse C4d staining, or more extensive microvascular inflammation [ie, glomerulitis score + peritubular capillary score ≥4] on biopsy) [
         <a href="#rid64">
          64
         </a>
         ]. For all patients, we also augment maintenance immunosuppression, as discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7356.html" rel="external">
          "Kidney transplantation in adults: Maintenance immunosuppressive therapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We administer glucocorticoids using the same approach as described above for patients diagnosed with ABMR within the first year posttransplant. (See
         <a class="local">
          'Patients who are ≤1 year posttransplant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We administer
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         at a dose of 200 mg/kg every two weeks for three doses. In patients with obesity, some centers determine the IVIG dose based upon the patient's ideal body weight (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ). Sucrose-free IVIG solutions that are no more than 5 percent concentrated are preferred, to decrease the risk of acute kidney injury. (See
         <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">
          "Overview of intravenous immune globulin (IVIG) therapy"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">
          "Intravenous immune globulin: Adverse effects", section on 'Acute kidney injury'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         If
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         is given, we administer a single dose of 375 mg/m
         <sup>
          2
         </sup>
         after completion of
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         .
        </p>
        <p>
        </p>
        <p>
         There is no high-quality evidence to guide the optimal therapy of patients with ABMR who present after the first year posttransplant. Our approach of treating later-onset ABMR without plasmapheresis is supported by observational data suggesting that plasmapheresis (in combination with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and glucocorticoids) is less effective at improving graft function in patients with ABMR after the first posttransplant year than in those with ABMR within the first posttransplant year [
         <a href="#rid65">
          65
         </a>
         ]. Evidence in support of IVIG and glucocorticoids is presented elsewhere in this topic. (See
         <a class="local">
          'Patients who are ≤1 year posttransplant'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H2180299734">
         <span class="h3">
          Prophylactic measures for all patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         In all patients who are treated for active ABMR, we recommence antimicrobial and antiviral prophylaxis with a regimen that is identical to that administered in the immediate posttransplant period. This includes prophylaxis against
         <em>
          Pneumocystis
         </em>
         pneumonia, cytomegalovirus (CMV) infection and disease, and herpes simplex infection (in patients who are at low CMV risk) for three months. In addition, we also administer antifungal prophylaxis and a prophylactic histamine-2 (H2) blocker for prevention of peptic ulcer disease, although this practice may vary by transplant center. A detailed discussion of the different prophylactic regimens is presented separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">
          "Prophylaxis of infections in solid organ transplantation", section on 'Pneumocystis pneumonia'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/105281.html" rel="external">
          "Prevention of cytomegalovirus disease in kidney transplant recipients", section on 'Universal prophylaxis (high risk)'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">
          "Prophylaxis of infections in solid organ transplantation", section on 'Antifungal prophylaxis'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2755308070">
         <span class="h3">
          Monitoring and modifying therapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Our approach to monitoring patients during therapy for active ABMR depends upon whether the patient is hospitalized for treatment or treated as an outpatient. As mentioned above, patients with active ABMR can be treated on an outpatient basis, but we advocate inpatient admission for patients with comorbidities (eg, diabetes), given the complexity of the treatment regimen.
        </p>
        <p>
         In patients who are treated in the outpatient setting, we monitor serum creatinine, electrolytes, and a complete blood count prior to each plasmapheresis session or on a weekly basis for four weeks if plasmapheresis is not performed. Patients who receive plasmapheresis are seen and evaluated during plasmapheresis sessions and then in the clinic at four weeks from the start of therapy; those who do not receive plasmapheresis undergo weekly labs for one month and monthly thereafter. All patients are seen for follow-up in the clinic at three months from the start of treatment, at which time we measure a DSA level. There is no consensus on the role of DSA monitoring after plasmapheresis, and clinical practice varies. We consider an allograft biopsy if a biopsy has not been performed earlier in the course of treatment and if there is no improvement in kidney function [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         Data on the reversal of ABMR are limited [
         <a href="#rid4">
          4,64,70
         </a>
         ]. In general, one-year graft survival after treatment of clinical and subclinical ABMR is approximately 80 and 95 percent, respectively [
         <a href="#rid70">
          70
         </a>
         ]. Patients are considered to have a successful reversal of ABMR if they meet all of the following parameters within three months of treatment:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decrease in serum creatinine to within 20 to 30 percent of the baseline level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decrease in proteinuria to the baseline level
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decrease in immunodominant DSA by &gt;50 percent
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Resolution of changes associated with ABMR on repeat kidney biopsy (see
         <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">
          "Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Active antibody-mediated rejection'
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Most patients with ABMR with a successful response to antirejection therapy will demonstrate an improvement in serum creatinine within seven days of treatment. Modification of therapy is based upon the response to initial therapy:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with a decrease in serum creatinine in response to therapy, we increase the maintenance
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         dose to achieve a trough level 20 to 25 percent above the level at the time of rejection and resume routine monitoring of allograft function. For patients who are taking the immediate-release formulation of tacrolimus and cannot tolerate higher doses, extended-release tacrolimus, which has fewer side effects and may allow for a higher and therapeutic trough to be obtained, is an alternative option [
         <a href="#rid73">
          73
         </a>
         ]. Typically, maintenance immunosuppression is also augmented by increasing the daily dose of oral
         <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">
          prednisone
         </a>
         and maximizing the dose of the antiproliferative agent (eg,
         <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">
          mycophenolate
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/14039.html" rel="external">
          "Overview of care of the adult kidney transplant recipient", section on 'Monitoring kidney allograft function'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7995.html" rel="external">
          "Pharmacology of cyclosporine and tacrolimus", section on 'Switching formulations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients without any decrease in serum creatinine after seven days of rejection treatment are considered to be unresponsive to initial treatment. In such patients, ongoing rejection and/or another cause of kidney allograft dysfunction should be suspected, and a repeat kidney allograft biopsy should be performed. Our subsequent approach depends upon the histopathological and clinical findings of the patient. If the biopsy reveals no evidence of an acute, reversible process or reveals extensive fibrosis (indicating nonviable kidney tissue), we typically discontinue treatment of acute rejection. If the biopsy demonstrates evidence of persistent active ABMR, second-line agents for the treatment of ABMR can be used as rescue therapy. However, the intensity of additional therapy with plasmapheresis and other agents such as
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         and anticomplement therapy should be weighed against preexisting comorbidities and the risk of infectious and malignant complications. (See
         <a class="local">
          'Second-line therapies for refractory ABMR'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H4174974161">
         <span class="h2">
          Second-line therapies for refractory ABMR
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with active ABMR will respond to a combination of glucocorticoids, plasmapheresis,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . However, in patients who do not respond to initial treatment with this combination, the following therapies can be considered as rescue therapy.
        </p>
        <p class="headingAnchor" id="H3533433427">
         <span class="h3">
          Proteasome inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          Bortezomib
         </a>
         is a proteasome inhibitor that is commonly used for the treatment of multiple myeloma. The drug is particularly effective against differentiated plasma cells because of the high rate of protein synthesis in these cells [
         <a href="#rid74">
          74,75
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6647.html" rel="external">
          "Multiple myeloma: Initial treatment"
         </a>
         .)
        </p>
        <p>
         At our centers, we do not routinely use
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         in patients with refractory ABMR. However, several case reports/series have demonstrated the effectiveness of bortezomib in treating ABMR, successfully reversing acute rejection, and/or reducing DSAs [
         <a href="#rid76">
          76-81
         </a>
         ]. In one study, two patients treated with bortezomib for active ABMR showed a transient decrease in bone marrow plasma cells in vivo and persistent alterations in alloantibody specificities. Total IgG levels were unchanged, suggesting that proteasome activity is important for plasma cell longevity and its inhibition may control antibody production in vivo [
         <a href="#rid76">
          76
         </a>
         ]. In another study, two patients underwent bortezomib-based therapy for active ABMR occurring within the first two weeks posttransplant [
         <a href="#rid80">
          80
         </a>
         ]. Both patients experienced prompt reversal of ABMR and elimination of detectable DSA within 14 days of treatment. However, a follow-up study of 28 patients with active ABMR found that bortezomib therapy was associated with better DSA and histologic response in patients with early (within six months of transplant) rejection but not late ABMR [
         <a href="#rid81">
          81
         </a>
         ].
        </p>
        <p>
         The use of
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         in patients with late ABMR was examined in a trial that randomly assigned 44 kidney transplant recipients who were ≥6 months posttransplant, had a positive DSA, and had histologic evidence of active or chronic ABMR to two cycles of bortezomib or placebo [
         <a href="#rid82">
          82
         </a>
         ]. At 24 months posttreatment, there were no significant differences between the groups in patient and graft survival, median measured glomerular filtration rate (GFR), proteinuria, DSA levels, or morphologic or molecular rejection phenotypes in allograft biopsy samples. However, bortezomib-treated patients experienced higher rates of gastrointestinal and hematologic toxicity.
        </p>
        <p class="headingAnchor" id="H1137680932">
         <span class="h3">
          Complement inhibitors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Activation of the complement pathway is an important step in the pathogenesis of ABMR, providing the rationale for the use of complement inhibition in the treatment of ABMR.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eculizumab
         </strong>
         <strong>
         </strong>
         –
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          Eculizumab
         </a>
         is a fully humanized, monoclonal antibody directed against the C5 fragment of the complement cascade and inhibits the generation of the membrane attack complex. It has received US Food and Drug Administration (FDA) approval for treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (aHUS). (See
         <a class="medical medical_review" href="/z/d/html/6084.html" rel="external">
          "Complement-mediated hemolytic uremic syndrome in children", section on 'Complement blockade (eculizumab)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7163.html" rel="external">
          "Treatment and prognosis of paroxysmal nocturnal hemoglobinuria", section on 'Eculizumab'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          eculizumab
         </a>
         is used, we typically administer 1200 mg IV as the initial dose, followed by 900 mg IV weekly for three to four weeks. Treatment with eculizumab may be associated with life-threatening and fatal meningococcal infections. Patients should receive meningococcal vaccination at least two weeks prior to initiation of eculizumab whenever possible. We also administer daily antimicrobial prophylaxis for prevention of meningococcal infection in patients treated with eculizumab, despite vaccination, due to increased infection risk with immunosuppression. (See
         <a class="medical medical_review" href="/z/d/html/1274.html" rel="external">
          "Treatment and prevention of meningococcal infection", section on 'Patients receiving C5 inhibitors'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In kidney transplantation,
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          eculizumab
         </a>
         has been used to prevent ABMR in highly sensitized recipients who undergo desensitization [
         <a href="#rid11">
          11
         </a>
         ]. There are also reports of its successful use as a salvage agent in treating refractory active ABMR [
         <a href="#rid83">
          83-89
         </a>
         ]. The doses used have been similar to those used for the treatment of aHUS, and the duration of dosing has been variable. The lack of randomized, controlled trials proving its efficacy and safety has limited its use in kidney transplant recipients. In addition, ABMR has occurred in kidney transplant recipients who were receiving eculizumab for other indications, such as receipt of a positive crossmatch kidney or HUS [
         <a href="#rid90">
          90,91
         </a>
         ]. Eculizumab has not been shown to be effective for the treatment of C4d-negative active and chronic ABMR, suggesting that its efficacy may be limited to acute, complement-mediated processes [
         <a href="#rid11">
          11,90,92
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          C1 inhibitors
         </strong>
         – Binding of anti-human leukocyte antigen (HLA) DSAs to complement fraction C1q, the first component in the activation of the complement cascade, has been associated with poor graft outcomes and severe phenotypes of ABMR [
         <a href="#rid32">
          32
         </a>
         ]. These findings have provided the rationale for the use of proximal complement inhibition using C1 inhibitors (C1 INHs) in the treatment of ABMR. However, C1 INHs are not routinely used in clinical practice for ABMR pending further studies of their efficacy and safety in this setting. C1 INHs have been approved by the FDA for use in patients with hereditary angioedema. (See
         <a class="medical medical_review" href="/z/d/html/8104.html" rel="external">
          "Hereditary angioedema: Acute treatment of angioedema attacks", section on 'First-line agents: Dosing, efficacy, and adverse reactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Evidence supporting the use of C1 INHs for active ABMR is limited [
         <a href="#rid93">
          93,94
         </a>
         ]. In a phase IIb, multicenter trial that randomly assigned 18 kidney transplant recipients with biopsy-proven, active ABMR to receive C1 INH 20,000 units or placebo every other day for two weeks as adjunct therapy to plasmapheresis,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , resolution of ABMR occurred in 78 and 67 percent of patients treated with C1 INH and placebo, respectively [
         <a href="#rid93">
          93
         </a>
         ]. There was no significant difference between the groups in posttreatment kidney histopathology or graft survival on day 20; however, a trend toward sustained improvement in graft function at day 90 was observed in the C1 INH group.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1324628406">
         <span class="h3">
          Less frequently used therapies
         </span>
         <span class="headingEndMark">
          —
         </span>
         Less frequently used therapies for refractory ABMR include the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Immunoadsorption
         </strong>
         – Immunoadsorption with protein A (IA) has been used to reverse ABMR [
         <a href="#rid95">
          95,96
         </a>
         ]. In the only controlled, open-label trial, 10 patients with severe ABMR were randomly assigned to IA or no IA (with the option of rescue IA after three weeks) [
         <a href="#rid96">
          96
         </a>
         ]. All IA-treated patients responded to therapy (although one death occurred independent of IA), while four control patients remained dialysis dependent. Rescue IA was not successful.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         While not available in the United States, selective IA treatment is an attractive alternative to the nonselective combination of plasmapheresis and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         . Given the improved outcomes in treating ABMR with plasmapheresis and IVIG, as compared with historical controls, and with IA, as compared with a control group in this small study, further analysis would ideally compare the two treatment methods in a larger number of patients. Although both forms of treatment are expensive, the selective modality of IA without a requirement for IVIG administration would appear preferable if similar outcomes are evident. As previously described, the relative contribution of IVIG or plasmapheresis in treating ABMR is unclear, and further analysis of IA may assist in clarifying this issue.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Splenectomy
         </strong>
         – We do not routinely perform splenectomy in patients with ABMR, given the lack of evidence that this intervention is safer or more efficacious than available medical therapy. However, some centers consider splenectomy in treating ABMR refractory to plasmapheresis and/or
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         [
         <a href="#rid97">
          97,98
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Four kidney transplant recipients (two ABO incompatible, one crossmatch positive, one with known risk factors) who were diagnosed with an ABMR and failed standard therapy (average 11 days) with glucocorticoids, plasmapheresis,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         ,
         <a class="drug drug_general" data-topicid="10026" href="/z/d/drug information/10026.html" rel="external">
          rabbit antithymocyte globulin
         </a>
         (rATG)-Thymoglobulin, and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         (three patients) or
         <a class="drug drug_general" data-topicid="8725" href="/z/d/drug information/8725.html" rel="external">
          alemtuzumab
         </a>
         (one patient) were treated with laparoscopic splenectomy [
         <a href="#rid97">
          97
         </a>
         ]. Urine output improved immediately, and serum creatinine decreased within 48 hours.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Five patients who underwent a living-donor kidney transplant after desensitization for a positive crossmatch had ABMR [
         <a href="#rid98">
          98
         </a>
         ]. After rescue attempts with plasmapheresis and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         failed, they underwent splenectomy followed by plasmapheresis and IVIG. Allograft function returned within 48 hours of the procedure.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3357521641">
         <span class="h2">
          Special populations
         </span>
        </p>
        <p class="headingAnchor" id="H3926747924">
         <span class="h3">
          Patients with mixed acute rejection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with mixed acute rejection (ie, concurrent histologic evidence of both ABMR and acute T cell-mediated (cellular) rejection [TCMR; Banff grade 2A or greater]) should be treated for both ABMR and TCMR. We treat with the combination of glucocorticoids,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and plasmapheresis (in patients ≤1 year posttransplant), as detailed above (see
         <a class="local">
          'Approach to initial therapy'
         </a>
         above), and add rATG-Thymoglobulin to the treatment regimen. In this setting, we generally perform plasmapheresis and administer IVIG on an alternate-day schedule (eg, Monday, Wednesday, Friday, and Sunday) for a minimum of four treatments. We administer rATG-Thymoglobulin (1.5 to 3 mg/kg) on an alternate-day schedule on the intervening days (eg, Tuesday, Thursday, and Saturday), for a total of three doses.
        </p>
        <p>
         A discussion of the evidence for the use of rATG-Thymoglobulin in patients with acute TCMR is presented elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7358.html" rel="external">
          "Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection", section on 'Banff grade II or III rejection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2722546213">
         <span class="h3">
          Patients with subclinical rejection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Subclinical rejection is defined as the presence of histologic evidence of acute rejection on biopsy without an elevation in the serum creatinine concentration. This diagnosis is typically established by a protocol, or surveillance, biopsy, which is obtained at a protocol-driven, prespecified time after transplant rather than for a clinical indication. (See
         <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">
          "Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Subclinical rejection'
         </a>
         .)
        </p>
        <p>
         In all patients who are found to have evidence of subclinical ABMR, we use the same therapeutic approach as that used to treat patients with clinical ABMR (see
         <a class="local">
          'Approach to initial therapy'
         </a>
         above), based upon evidence from retrospective studies that suggest that treatment of subclinical ABMR may be associated with improved graft outcomes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study compared graft outcomes of 219 kidney transplant recipients with ABMR (77 subclinical, 142 clinical) with matched controls without ABMR [
         <a href="#rid70">
          70
         </a>
         ]. One- and five-year graft survival among patients with subclinical ABMR were 96 and 76 percent, respectively, compared with 97 and 88 percent in controls. Overall, the risk of graft loss in patients with subclinical ABMR was 2.15-fold greater than that in matched controls. However, there was no significant difference in graft loss between those with treated subclinical ABMR and the controls.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study that compared graft outcomes among 220 kidney transplant recipients (118 with clinical ABMR, 25 with subclinical ABMR, and 77 controls without ABMR), those with clinical and subclinical ABMR received similar treatment that included pulse glucocorticoids,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and plasmapheresis (for those with rejection within three months of transplant), with or without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         [
         <a href="#rid99">
          99
         </a>
         ]. Rates of death-censored graft failure were not significantly different between the subclinical ABMR and control groups.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3061966057">
         <span class="h3">
          Patients with C4d-negative ABMR
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some patients have histologic evidence of ABMR and a positive DSA but have little or no C4d staining in the peritubular capillaries, an entity recognized as C4d-negative ABMR. Such patients should be treated using the same approach as that for patients with C4d-positive ABMR [
         <a href="#rid100">
          100
         </a>
         ]. (See
         <a class="local">
          'Approach to initial therapy'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">
          "Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Active antibody-mediated rejection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H981966709">
         <span class="h3">
          Patients with a non-HLA DSA
         </span>
         <span class="headingEndMark">
          —
         </span>
         ABMR can also occur in patients with non-human leukocyte antigen (HLA) donor-specific antibodies (DSAs), such as anti-angiotensin II type 1 (AT1) receptor antibodies [
         <a href="#rid101">
          101
         </a>
         ] and antiendothelial antibodies [
         <a href="#rid102">
          102
         </a>
         ]. The immunosuppressive treatment of ABMR in such patients is generally the same as that in patients with ABMR and an anti-HLA DSA. Patients who are found to have an anti-AT1 receptor antibody should receive, in addition to immunosuppressive therapy, an angiotensin II receptor blocker, which may inhibit AT1-receptor antibody-mediated effects [
         <a href="#rid101">
          101,103
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">
          "Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Laboratory findings'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3636578960">
         <span class="h1">
          TREATMENT OF CHRONIC ANTIBODY-MEDIATED REJECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic ABMR, the most common cause of graft failure, is more difficult to treat than active ABMR since irreversible tissue damage has already occurred to the kidney allograft [
         <a href="#rid2">
          2,19
         </a>
         ]. Although evidence suggests that the treatment of antibody-mediated injury requires a combination of strategies to inhibit B cell development, maturation, and activity, it is not clear which combination therapy is safe and effective in patients with chronic ABMR [
         <a href="#rid4">
          4,19,92,104-106
         </a>
         ].
        </p>
        <p>
         For patients with chronic ABMR, we suggest initial therapy with glucocorticoids and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) rather than other therapies. In addition, some experts administer
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         if the patient is younger (eg, age &lt;70 years), has better allograft function (eg, estimate glomerular filtration rate [eGFR] ≥20 mL/min/1.73 m
         <sup>
          2
         </sup>
         and lower chronicity scores on biopsy [ie, interstitial fibrosis + tubular atrophy + fibrous intimal thickening + allograft glomerulopathy &lt;8]), and has evidence of severe disease (eg, higher donor-specific antibodies (DSA), diffuse C4d staining, or more extensive microvascular inflammation [ie, glomerulitis score + peritubular capillary score ≥4] on biopsy) [
         <a href="#rid64">
          64
         </a>
         ]. This treatment approach is the same as that used for patients with active ABMR that occurs after the first year posttransplant. If the patient does not respond to initial therapy, we treat with
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         . (See
         <a class="local">
          'Patients who are &gt;1 year posttransplant'
         </a>
         above.)
        </p>
        <p>
         There is no high-quality evidence to guide the optimal therapy of chronic ABMR, and evidence supporting our treatment approach comes primarily from observational studies [
         <a href="#rid19">
          19
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In an observational study of 123 kidney transplant recipients with biopsy-proven chronic ABMR, treatment with glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         was associated with a lower risk of graft loss (hazard ratio [HR] 0.44, 95% CI 0.20-0.96) [
         <a href="#rid19">
          19
         </a>
         ]. Patients with surviving grafts had a more significant reduction in DSAs, suggesting the need for more mechanistic interventional clinical trials targeting DSA in patients with chronic ABMR.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In another study of 78 kidney transplant recipients diagnosed with late (defined as &gt;3 months after transplant) ABMR (40 with chronic active ABMR), treatment with glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         with or without
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         was associated with a decline in DSA, microvascular inflammation, and C4d Banff scores [
         <a href="#rid64">
          64
         </a>
         ]. In multivariate analyses, use of rituximab was associated with a lower risk of graft loss (HR 0.23, 95% CI 0.06-0.84).
        </p>
        <p>
        </p>
        <p>
         Limited data suggest that treatment with interleukin (IL) 6 blockade may benefit patients with chronic ABMR. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study has assessed the use of
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         , a monoclonal antibody against the IL-6 receptor, as rescue therapy in 36 kidney transplant patients with chronic ABMR who were unresponsive to standard-of-care treatment with
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         , with or without plasma exchange [
         <a href="#rid107">
          107
         </a>
         ]. Tocilizumab was administered as 8 mg/kg monthly, with a maximal dose of 800 mg for 6 to 25 months. Graft and patient survival rates in tocilizumab-treated patients were 80 and 91 percent at six years posttreatment, respectively. Significant reductions in DSAs and stabilization of kidney allograft function were observed at two years. No significant adverse events or severe adverse events were reported.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A phase II, randomized pilot trial evaluated the safety and efficacy of the anti-IL-6 antibody clazakizumab in 20 kidney transplant recipients with late (≥1 year posttransplant) ABMR (18 with chronic active ABMR) [
         <a href="#rid108">
          108
         </a>
         ]. Patients were randomly assigned to receive subcutaneous clazakizumab or placebo monthly for 12 weeks, followed by a 40-week open-label extension, during which all patients received clazakizumab. Five patients (25 percent) receiving active treatment developed serious infections, and two (10 percent) developed diverticulitis, leading to withdrawal from the study. Patients receiving clazakizumab experienced a decrease in DSA. In 18 patients, allograft biopsies after 51 weeks revealed a negative molecular ABMR score in seven (39 percent), disappearance of capillary C4d deposits in five (28 percent), and resolution of morphologic ABMR activity in four (22 percent). While proteinuria remained stable, mean decline in eGFR over the first 12 weeks was slower with clazakizumab compared with placebo (-0.96 versus -2.43 mL/min/1.73 m
         <sup>
          2
         </sup>
         per month). During the open-label extension phase, the slope of eGFR decline among patients who were switched from placebo to clazakizumab improved and no longer differed significantly from that of patients initially assigned to clazakizumab.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A larger randomized, placebo-controlled trial evaluating clazakizumab for the treatment of chronic ABMR is in progress (NCT03744910).
        </p>
        <p>
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8836" href="/z/d/drug information/8836.html" rel="external">
          Eculizumab
         </a>
         and
         <a class="drug drug_general" data-topicid="8509" href="/z/d/drug information/8509.html" rel="external">
          bortezomib
         </a>
         have not been shown to be effective in patients with chronic ABMR [
         <a href="#rid92">
          92
         </a>
         ].
        </p>
        <p>
         The diagnosis of chronic ABMR in kidney transplant recipients is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/7352.html" rel="external">
          "Kidney transplantation in adults: Clinical features and diagnosis of acute kidney allograft rejection", section on 'Chronic rejection'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2907642410">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/110754.html" rel="external">
          "Society guideline links: Kidney transplantation"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3982748">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Overview
         </strong>
         – Antibody-mediated rejection (ABMR) is the most common cause of immune-mediated allograft failure after kidney transplantation. Prevention and treatment of ABMR requires a combination of strategies to inhibit B cell development, maturation, and activity. Active and chronic ABMR are both associated with poor outcomes. (See
         <a class="local">
          'Predictors of outcome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Our approach to the prevention of ABMR depends upon the detection of donor-specific antibody (DSA) prior to (preexisting DSA) or after (de novo DSA) transplant:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Preexisting DSA
         </strong>
         – Our approach is as follows (see
         <a class="local">
          'Patients with preexisting DSA before transplant'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In patients with a potential living donor, the approach depends upon the results of the most recent crossmatch. In patients with a positive complement-dependent cytotoxicity (CDC) crossmatch or a strongly positive flow crossmatch, we prefer to use kidney paired donation (KPD) programs rather than desensitization, given the high risk of ABMR and graft loss in such patients. In patients with a positive virtual crossmatch or a mild to moderate flow crossmatch (ie, median channel shift of &lt;200), we employ human leukocyte antigen (HLA) desensitization strategies.
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         In patients without a potential living donor, we employ HLA desensitization strategies.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          De novo DSA
         </strong>
         – In patients with a de novo DSA after transplant, prevention should focus on addressing nonadherence and under-immunosuppression while balancing the safety and efficacy of long-term immunosuppression. (See
         <a class="local">
          'Patients with de novo DSA after transplant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of active ABMR
         </strong>
         – The primary goal of treating ABMR is to remove existing DSAs and to eradicate the clonal population of B cells or plasma cells that is responsible for their production.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Initial therapy
         </strong>
         – Our approach to initial therapy depends upon the timing of the diagnosis of ABMR (
         <a class="graphic graphic_algorithm graphicRef116370" href="/z/d/graphic/116370.html" rel="external">
          algorithm 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          Within one year posttransplant
         </strong>
         – For most patients who are diagnosed with active ABMR within the first year posttransplant, we suggest initial therapy with the combination of glucocorticoids, plasmapheresis, and intravenous
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          immune globulin
         </a>
         (IVIG) rather than other therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In addition, some experts administer
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         if the patient is &lt;70 years old, has better allograft function, and has severe disease. For all patients, we augment other components of maintenance immunosuppression as needed. (See
         <a class="local">
          'Patients who are ≤1 year posttransplant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         <strong>
          After one year posttransplant
         </strong>
         – For most patients who are diagnosed with active ABMR after the first year posttransplant, we suggest initial therapy with glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         rather than glucocorticoids, plasmapheresis, and IVIG (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). We do
         <strong>
          not
         </strong>
         perform plasmapheresis in such patients because of the lack of evidence supporting the safety and efficacy of plasmapheresis in late-onset ABMR. In addition, some experts administer
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         if the patient is &lt;70 years old, has better allograft function, and has severe disease. For all patients, we also augment maintenance immunosuppression, as discussed elsewhere. (See
         <a class="local">
          'Patients who are &gt;1 year posttransplant'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Prophylaxis
         </strong>
         – In all patients who are treated for active ABMR, we recommence antimicrobial and antiviral prophylaxis with a regimen that is identical to that administered in the immediate posttransplant period. In addition, we also administer antifungal prophylaxis and a prophylactic histamine-2 (H2) blocker for prevention of peptic ulcer disease, although this practice may vary by transplant center. (See
         <a class="local">
          'Prophylactic measures for all patients'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Refractory ABMR
         </strong>
         – Most patients with active ABMR will respond to a combination of glucocorticoids, plasmapheresis,
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         , and
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         . In patients who do not respond to initial treatment with this combination, rescue therapies include proteasome inhibitors, complement inhibitors, immunoadsorption, or splenectomy. (See
         <a class="local">
          'Second-line therapies for refractory ABMR'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment of chronic ABMR
         </strong>
         – Chronic ABMR, the most common cause of graft failure, is more difficult to treat than active ABMR since irreversible tissue damage has already occurred in the allograft. It is not clear which combination therapy is safe and effective in patients with chronic ABMR. For patients with chronic ABMR, we suggest initial therapy with glucocorticoids and
         <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">
          IVIG
         </a>
         rather than other therapies (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). In addition, some experts administer
         <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">
          rituximab
         </a>
         if the patient is &lt;70 years old, has better allograft function, and has severe disease. If the patient does not respond to initial therapy, we treat with
         <a class="drug drug_general" data-topicid="10208" href="/z/d/drug information/10208.html" rel="external">
          tocilizumab
         </a>
         . (See
         <a class="local">
          'Treatment of chronic antibody-mediated rejection'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H380841454">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Christina Klein, MD, and Arjang Djamali, MD, MS, FASN, who contributed to earlier versions of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12:1157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant 2012; 12:388.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9:527.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djamali A, Kaufman DB, Ellis TM, et al. Diagnosis and management of antibody-mediated rejection: current status and novel approaches. Am J Transplant 2014; 14:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M, Loupy A, Lefaucheur C, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant 2018; 18:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant 2020; 20:2318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mengel M, Loupy A, Haas M, et al. Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation. Am J Transplant 2020; 20:2305.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Farkash EA, Colvin RB. Diagnostic challenges in chronic antibody-mediated rejection. Nat Rev Nephrol 2012; 8:255.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection. Curr Opin Organ Transplant 2010; 15:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant 2010; 10:1812.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cornell LD, Schinstock CA, Gandhi MJ, et al. Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year. Am J Transplant 2015; 15:1293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mauiyyedi S, Pelle PD, Saidman S, et al. Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries. J Am Soc Nephrol 2001; 12:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Drachenberg CB, Papadimitriou JC. Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Transplantation 2013; 95:1073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schinstock CA, Mannon RB, Budde K, et al. Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group. Transplantation 2020; 104:911.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan SC, Pescovitz MD. Presensitization: the problem and its management. Clin J Am Soc Nephrol 2006; 1:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn TB, Noreen H, Gillingham K, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant 2011; 11:2132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupy A, Haas M, Solez K, et al. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. Am J Transplant 2017; 17:28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amico P, Hönger G, Mayr M, et al. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009; 87:1681.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Redfield RR, Ellis TM, Zhong W, et al. Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria. Hum Immunol 2016; 77:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gaston RS, Cecka JM, Kasiske BL, et al. Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure. Transplantation 2010; 90:68.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Matignon M, Muthukumar T, Seshan SV, et al. Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection. Transplantation 2012; 94:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feucht HE, Schneeberger H, Hillebrand G, et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43:1333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Djamali A, Muth BL, Ellis TM, et al. Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients. Kidney Int 2013; 83:1185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupy A, Hill GS, Suberbielle C, et al. Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA). Am J Transplant 2011; 11:56.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einecke G, Sis B, Reeve J, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant 2009; 9:2520.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patri P, Seshan SV, Matignon M, et al. Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy. Kidney Int 2016; 89:450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kamal L, Broin PÓ, Bao Y, et al. Clinical, Histological, and Molecular Markers Associated With Allograft Loss in Transplant Glomerulopathy Patients. Transplantation 2015; 99:1912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M, Mirocha J, Reinsmoen NL, et al. Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies. Kidney Int 2017; 91:729.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21:1398.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parajuli S, Joachim E, Alagusundaramoorthy S, et al. Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure. Kidney Int Rep 2019; 4:1057.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefaucheur C, Viglietti D, Bentlejewski C, et al. IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury. J Am Soc Nephrol 2016; 27:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupy A, Lefaucheur C, Vernerey D, et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369:1215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yell M, Muth BL, Kaufman DB, et al. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection. Transplantation 2015; 99:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aubert O, Loupy A, Hidalgo L, et al. Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. J Am Soc Nephrol 2017; 28:1912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Halloran PF, de Freitas DG, Einecke G, et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010; 10:2223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haas M. The Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations. Am J Transplant 2016; 16:1352.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everly MJ, Everly JJ, Arend LJ, et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009; 9:1063.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everly MJ, Terasaki PI, Trivedi HL. Durability of antibody removal following proteasome inhibitor-based therapy. Transplantation 2012; 93:572.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banfi G, Villa M, Cresseri D, Ponticelli C. The clinical impact of chronic transplant glomerulopathy in cyclosporine era. Transplantation 2005; 80:1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Irish W, Nickerson P, Astor BC, et al. Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation. Transplantation 2021; 105:648.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupy A, Lefaucheur C, Vernerey D, et al. Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection. J Am Soc Nephrol 2014; 25:2267.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garg N, Mandelbrot DA, Parajuli S, et al. The clinical value of donor-derived cell-free DNA measurements in kidney transplantation. Transplant Rev (Orlando) 2021; 35:100649.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bu L, Gupta G, Pai A, et al. Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study. Kidney Int 2022; 101:793.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loupy A, Aubert O, Orandi BJ, et al. Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study. BMJ 2019; 366:l4923.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orandi BJ, Garonzik-Wang JM, Massie AB, et al. Quantifying the risk of incompatible kidney transplantation: a multicenter study. Am J Transplant 2014; 14:1573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mohan S, Palanisamy A, Tsapepas D, et al. Donor-specific antibodies adversely affect kidney allograft outcomes. J Am Soc Nephrol 2012; 23:2061.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jordan SC, Tyan D, Stablein D, et al. Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial. J Am Soc Nephrol 2004; 15:3256.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: the University of Wisconsin initial experience. Transplantation 2011; 92:12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orandi BJ, Luo X, Massie AB, et al. Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. N Engl J Med 2016; 374:940.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med 2011; 365:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Melcher ML, Leeser DB, Gritsch HA, et al. Chain transplantation: initial experience of a large multicenter program. Am J Transplant 2012; 12:2429.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roodnat JI, Kal-van Gestel JA, Zuidema W, et al. Successful expansion of the living donor pool by alternative living donation programs. Am J Transplant 2009; 9:2150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham TA, Lee JI, Melcher ML. Kidney paired exchange and desensitization: Strategies to transplant the difficult to match kidney patients with living donors. Transplant Rev (Orlando) 2017; 31:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery RA, Zachary AA, Ratner LE, et al. Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation. JAMA 2005; 294:1655.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amrouche L, Aubert O, Suberbielle C, et al. Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA: The Necker High-Risk Transplant Program. Transplantation 2017; 101:2440.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tait BD, Süsal C, Gebel HM, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Al Meshari K, Pall A, Elgamal H, et al. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum. Clin Transpl 2010; :383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           OʼLeary JG, Samaniego M, Barrio MC, et al. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients. Transplantation 2016; 100:39.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liefeldt L, Brakemeier S, Glander P, et al. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12:1192.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and Long-Term Outcomes in Kidney Transplantation. N Engl J Med 2016; 374:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Delgado JC, Fuller A, Ozawa M, et al. No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study. Transplantation 2009; 87:546.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velidedeoglu E, Cavaillé-Coll MW, Bala S, et al. Summary of 2017 FDA Public Workshop: Antibody-mediated Rejection in Kidney Transplantation. Transplantation 2018; 102:e257.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parajuli S, Mandelbrot DA, Muth B, et al. Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation. Transplant Direct 2017; 3:e227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamada C, Ramon DS, Cascalho M, et al. Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients. Transfusion 2015; 55:727.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wan SS, Ying TD, Wyburn K, et al. The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis. Transplantation 2018; 102:557.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lee CY, Lin WC, Wu MS, et al. Repeated cycles of high-dose intravenous immunoglobulin and plasmapheresis for treatment of late antibody-mediated rejection of renal transplants. J Formos Med Assoc 2016; 115:845.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Einecke G, Bräsen J, Schwarz A, et al. Treatment of late antibody-mediated rejection: observations from clinical practice. Am J Transplant 2016; 16 (suppl 3).
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lefaucheur C, Nochy D, Andrade J, et al. Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009; 9:1099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orandi BJ, Chow EH, Hsu A, et al. Quantifying renal allograft loss following early antibody-mediated rejection. Am J Transplant 2015; 15:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sautenet B, Blancho G, Büchler M, et al. One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial. Transplantation 2016; 100:391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bailly E, Ville S, Blancho G, et al. An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. Transpl Int 2020; 33:786.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alhamad T, Venkatachalam K, Daloul R, et al. Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. Transplantation 2017; 101:e287.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jagannath S, Barlogie B, Berenson JR, et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005; 103:1195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perry DK, Burns JM, Pollinger HS, et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009; 9:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nigos JG, Arora S, Nath P, et al. Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen. Exp Clin Transplant 2012; 10:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Everly MJ, Everly JJ, Susskind B, et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008; 86:1754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flechner SM, Fatica R, Askar M, et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010; 90:1486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010; 89:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation 2011; 91:1218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskandary F, Regele H, Baumann L, et al. A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol 2018; 29:591.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orandi BJ, Zachary AA, Dagher NN, et al. Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation. Transplantation 2014; 98:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fan J, Tryphonopoulos P, Tekin A, et al. Eculizumab Salvage Therapy for Antibody-Mediated Rejection in a Desensitization-Resistant Intestinal Re-Transplant Patient. Am J Transplant 2015; 15:1995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto T, Watarai Y, Futamura K, et al. Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report. Transplant Proc 2017; 49:159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9:231.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kocak B, Arpali E, Demiralp E, et al. Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports. Transplant Proc 2013; 45:1022.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghirardo G, Benetti E, Poli F, et al. Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody. Pediatr Transplant 2014; 18:E1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eskandary F, Wahrmann M, Mühlbacher J, Böhmig GA. Complement inhibition as potential new therapy for antibody-mediated rejection. Transpl Int 2016; 29:392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burbach M, Suberbielle C, Brochériou I, et al. Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts. Transplantation 2014; 98:1056.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bentall A, Tyan DB, Sequeira F, et al. Antibody-mediated rejection despite inhibition of terminal complement. Transpl Int 2014; 27:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial. Am J Transplant 2017; 17:682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Montgomery RA, Orandi BJ, Racusen L, et al. Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study. Am J Transplant 2016; 16:3468.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Viglietti D, Gosset C, Loupy A, et al. C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study. Am J Transplant 2016; 16:1596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böhmig GA, Exner M, Watschinger B, et al. C4d deposits in renal allografts are associated with inferior graft outcome. Transplant Proc 2001; 33:1151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Böhmig GA, Wahrmann M, Regele H, et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007; 7:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaplan B, Gangemi A, Thielke J, et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007; 83:99.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Locke JE, Zachary AA, Haas M, et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007; 7:842.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parajuli S, Joachim E, Alagusundaramoorthy S, et al. Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes. Transplantation 2019; 103:1722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orandi BJ, Alachkar N, Kraus ES, et al. Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation. Am J Transplant 2016; 16:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dragun D, Müller DN, Bräsen JH, et al. Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005; 352:558.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun Q, Liu Z, Yin G, et al. Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases. Transplantation 2005; 79:1759.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fuss A, Hope CM, Deayton S, et al. C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies. Nephrology (Carlton) 2015; 20:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fehr T, Rüsi B, Fischer A, et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009; 87:1837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fehr T, Gaspert A. Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale. Transpl Int 2012; 25:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith RN, Malik F, Goes N, et al. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts. Transpl Immunol 2012; 27:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Choi J, Aubert O, Vo A, et al. Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients. Am J Transplant 2017; 17:2381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doberer K, Duerr M, Halloran PF, et al. A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection. J Am Soc Nephrol 2021; 32:708.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 7326 Version 33.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22429309" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22081892" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19191769" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Identifying specific causes of kidney allograft loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24401076" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Diagnosis and management of antibody-mediated rejection: current status and novel approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29243394" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32463180" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell- and antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32428337" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Banff 2019 Meeting Report: Molecular diagnostics in solid organ transplantation-Consensus for the Banff Human Organ Transplant (B-HOT) gene panel and open source multicenter validation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22450441" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Diagnostic challenges in chronic antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20009933" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20659089" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25731800" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Positive crossmatch kidney transplant recipients treated with eculizumab: outcomes beyond 1 year.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11181806" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Chronic humoral rejection: identification of antibody-mediated chronic renal allograft rejection by C4d deposits in peritubular capillaries.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23370711" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31895348" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Recommended Treatment for Antibody-mediated Rejection After Kidney Transplantation: The 2019 Expert Consensus From the Transplantion Society Working Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17699241" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Presensitization: the problem and its management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21812918" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Revisiting traditional risk factors for rejection and graft loss after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27862883" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19502960" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26867813" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Current outcomes of chronic active antibody mediated rejection - A large single center retrospective review using the updated BANFF 2013 criteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20463643" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22932115" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Concurrent acute cellular rejection is an independent risk factor for renal allograft failure in patients with C4d-positive antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8315947" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Capillary deposition of C4d complement fragment and early renal graft loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23447068" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21199348" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19843030" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26422505" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Development and validation of a prognostic index for allograft outcome in kidney recipients with transplant glomerulopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25675205" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical, Histological, and Molecular Markers Associated With Allograft Loss in Transplant Glomerulopathy Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28104301" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Differences in pathologic features and graft outcomes in antibody-mediated rejection of renal allografts due to persistent/recurrent versus de novo donor-specific antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20634297" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31440696" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Donor-Specific Antibodies in the Absence of Rejection Are Not a Risk Factor for Allograft Failure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26293822" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : IgG Donor-Specific Anti-Human HLA Antibody Subclasses and Kidney Allograft Antibody-Mediated Injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24066742" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Complement-binding anti-HLA antibodies and kidney-allograft survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25839705" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28255002" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20931696" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : An integrated view of molecular changes, histopathology and outcomes in kidney transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26696524" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : The Revised (2013) Banff Classification for Antibody-Mediated Rejection of Renal Allografts: Update, Difficulties, and Future Considerations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19344434" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22262128" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Durability of antibody removal following proteasome inhibitor-based therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16340780" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : The clinical impact of chronic transplant glomerulopathy in cyclosporine era.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33617203" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Change in Estimated GFR and Risk of Allograft Failure in Patients Diagnosed With Late Active Antibody-mediated Rejection Following Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24700874" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34507254" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The clinical value of donor-derived cell-free DNA measurements in kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34953773" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Clinical outcomes from the Assessing Donor-derived cell-free DNA Monitoring Insights of kidney Allografts with Longitudinal surveillance (ADMIRAL) study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31530561" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Prediction system for risk of allograft loss in patients receiving kidney transplants: international derivation and validation study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24913913" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Quantifying the risk of incompatible kidney transplantation: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23160511" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Donor-specific antibodies adversely affect kidney allograft outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15579530" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21512428" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Luminex-based desensitization protocols: the University of Wisconsin initial experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962729" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21793744" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Desensitization in HLA-incompatible kidney recipients and survival.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22812922" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Chain transplantation: initial experience of a large multicenter program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19624564" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Successful expansion of the living donor pool by alternative living donation programs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28284304" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Kidney paired exchange and desensitization: Strategies to transplant the difficult to match kidney patients with living donors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16204665" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Clinical results from transplanting incompatible live kidney donor/recipient pairs using kidney paired donation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28114171" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Long-term Outcomes of Kidney Transplantation in Patients With High Levels of Preformed DSA: The Necker High-Risk Transplant Program.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23238534" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21696055" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26680372" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22300538" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26816011" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Belatacept and Long-Term Outcomes in Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19307792" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : No occurrence of de novo HLA antibodies in patients with early corticosteroid withdrawal in a 5-year prospective randomized study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29470345" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Summary of 2017 FDA Public Workshop: Antibody-mediated Rejection in Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : KDIGO clinical practice guideline for the care of kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29536028" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Rituximab and Monitoring Strategies for Late Antibody-Mediated Rejection After Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25385678" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Efficacy of plasmapheresis on donor-specific antibody reduction by HLA specificity in post-kidney transplant recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29315141" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : The Treatment of Antibody-Mediated Rejection in Kidney Transplantation: An Updated Systematic Review and Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27542515" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Repeated cycles of high-dose intravenous immunoglobulin and plasmapheresis for treatment of late antibody-mediated rejection of renal transplants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Treatment of late antibody-mediated rejection: observations from clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19422335" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Comparison of combination Plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25611786" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Quantifying renal allograft loss following early antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26555944" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : One-year Results of the Effects of Rituximab on Acute Antibody-Mediated Rejection in Renal Transplantation: RITUX ERAH, a Multicenter Double-blind Randomized Placebo-controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32279367" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28422926" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18753647" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15690325" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18976291" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23216567" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Treatment of antibody-mediated rejection in kidney transplant recipients: a single-center experience with a bortezomib-based regimen.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19104417" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21042239" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20145517" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21617586" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29242250" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25121475" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25649227" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Eculizumab Salvage Therapy for Antibody-Mediated Rejection in a Desensitization-Resistant Intestinal Re-Transplant Patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28104125" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Efficacy of Eculizumab Therapy for Atypical Hemolytic Uremic Syndrome Recurrence and Antibody-Mediated Rejection Progress After Renal Transplantation With Preformed Donor-Specific Antibodies: Case Report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18976298" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23622614" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24266980" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26474721" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Complement inhibition as potential new therapy for antibody-mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24839895" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Report of the inefficacy of eculizumab in two cases of severe antibody-mediated rejection of renal grafts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24990476" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Antibody-mediated rejection despite inhibition of terminal complement.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27501352" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Eculizumab Therapy for Chronic Antibody-Mediated Injury in Kidney Transplant Recipients: A Pilot Randomized Controlled Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27184779" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Plasma-Derived C1 Esterase Inhibitor for Acute Antibody-Mediated Rejection Following Kidney Transplantation: Results of a Randomized Double-Blind Placebo-Controlled Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26693703" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : C1 Inhibitor in Acute Antibody-Mediated Rejection Nonresponsive to Conventional Therapy in Kidney Transplant Recipients: A Pilot Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11267232" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : C4d deposits in renal allografts are associated with inferior graft outcome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17109725" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17220802" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Successful rescue of refractory, severe antibody mediated rejection with splenectomy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17391127" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30507740" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Subclinical Antibody-mediated Rejection After Kidney Transplantation: Treatment Outcomes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26317487" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Presentation and Outcomes of C4d-Negative Antibody-Mediated Rejection After Kidney Transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15703421" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15973182" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Detectable circulating antiendothelial cell antibodies in renal allograft recipients with C4d-positive acute rejection: a report of three cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25726938" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : C4d-negative antibody-mediated rejection with high anti-angiotensin II type I receptor antibodies in absence of donor-specific antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19543061" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22394269" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : Antibody-mediated kidney allograft rejection: therapeutic options and their experimental rationale.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22960786" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28199785" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : Assessment of Tocilizumab (Anti-Interleukin-6 Receptor Monoclonal) as a Potential Treatment for Chronic Antibody-Mediated Rejection and Transplant Glomerulopathy in HLA-Sensitized Renal Allograft Recipients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33443079" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : A Randomized Clinical Trial of Anti-IL-6 Antibody Clazakizumab in Late Antibody-Mediated Kidney Transplant Rejection.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
